Abstract
Intellectual Disability (ID) is characterised by substantial limitations in cognitive function and adaptive behaviour, affecting 1-3% of the population. Protein O-GlcNAcylation is a posttranslational modification of nucleocytoplasmic proteins regulated by two opposing enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Recently, missense mutations in OGT have been shown to segregate with ID, associated with compensatory reduction of OGA expression, although it is unclear whether this is mechanistically linked to the disease. Here, we report a patient with a K885N de novo missense mutation in the C-terminal pseudo histone acetyltransferase domain of OGA, associated with ID, infantile spasms and autism. While the K885N mutation does not affect protein stability or activity in vitro, this residue sits in the canonical GCN5 acetyltransferase family acceptor binding cleft. Strikingly, mouse embryonic stem cells edited to harbour the K885N mutation show increased OGA turnover and defects in neurogenesis. Taken together, these data suggest a link between missense mutations in OGA and ID.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a Wellcome Trust Investigator Award (110061), a Novo Nordisk Foundation Laureate award (NNF21OC0065969) and a Villum Fonden Investigator (00054496) to D.M.F.v.A. C.W.M. is funded by the BBSRC EASTBIO Doctoral Training Programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Comit de protection des personnes (CPP) ILE DE France VI (Genedefi - CPP 74-12) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
